Recently, at the melanoma branch of the second CSCO-Junshi Bio-Tumor Immunity Summit Forum, the anti-PD-1 monoclonal antibody drug Teriplizumab Injection (Tuoyi®) "Yilu is accompanied by Bethune·Tuoyi" The charity donation project" successfully completed its mission and the melanoma indications were included in the national medical insurance catalogue to celebrate the landing ceremony.
After the implementation of the new medical insurance, compared with the previous charity assistance, it will further reduce the economic burden of melanoma patients and continue to increase the availability of anti-tumor drugs.
Professor Guo Jun from Peking University Cancer Hospital, Professor Niu Xiaohui from Beijing Jishuitan Hospital, Professor Pan Hongming from Shaw Hospital Affiliated to Zhejiang University School of Medicine and other melanoma experts, Shi Yuanyuan, Deputy Secretary-General of Beijing Bethune Charity Foundation, Duan Xin, Chief Commercial Officer of Junshi Bio Waiting for guests to attend the meeting.
Melanoma is known as the "king of cancer".
It is a malignant tumor that progresses quickly and is easy to metastasize.
For a long time, it lacks effective treatment.
At the end of 2018, Teriplimumab (Tuoyi®) independently developed by Junshi Biologics, a local innovative pharmaceutical company, was approved for marketing for the treatment of unresectable or metastatic melanoma that had previously failed systemic treatment.
At the end of 2020, Teriplizumab passed the national medical insurance negotiations and became the only anti-PD-1 monoclonal antibody used for the treatment of melanoma in the new version of the catalog.
At the meeting, many domestic experts in the field of melanoma and the management of Junshi Biotechnology jointly witnessed the landing ceremony of the inclusion of the melanoma indication of Teriplizumab (Tuoyi®) into the National Medical Insurance List.
Professor Guo Jun, deputy dean of Peking University Cancer Hospital, believes that tumor immunotherapy represented by anti-PD-1 monoclonal antibody has become a cornerstone drug for melanoma patients.
"Treplimumab is an important achievement of Chinese local innovation in the field of tumor immunotherapy.
Teriplimumab has shown excellent efficacy in the more common subtypes of acral and mucosal melanoma in our Asian population.
"Professor Guo Jun introduced, "Through medical insurance reimbursement, allowing more patients to receive the treatment of this innovative treatment of teriprizumab will bring better survival benefits to patients.
Teriplizumab is the first domestic monoclonal antibody drug targeting PD-1 approved for marketing in China.
Therefore, Junshi Bio has fully considered the availability of anti-tumor drugs in China and positioned the market price at similar products.
The 1/6 level of overseas pricing is the first to break the monopoly of imported similar drugs in the Chinese market, bringing new hope to melanoma patients.
Taking into account the financial situation of some patients who are still unable to afford medication, in February 2019, with the support of Junshi Bio, Beijing Bethune Charity Foundation launched the "Benefit Road-Bethune·Tuoyi Charity Donation Project" to relieve patients and The financial burden of his family allows more patients to receive timely treatment.
From April 2019 to February 2021, the project has been carried out in 142 cities in 30 provinces across the country, assisting more than 5,000 patients, and donating drugs worth nearly 200 million yuan.
Shi Yuanyuan, deputy secretary-general of Beijing Bethune Charity Foundation, fully affirmed Junshi Biology’s continuous improvement of the availability of high-quality innovative drugs to benefit patients, and active implementation of corporate social responsibility, and awarded Junshi Biology the "Yilu" Accompanied-Bethune · Tuoyi Public Welfare Donation Project Caring Donation Enterprise" award.
It is understood that after teriplizumab (Tuoyi®) is successfully included in the national medical insurance, it will take over the "Yilu Companion—Bethune·Tuoyi Public Welfare Donation Project", which will reduce the financial burden of patients to a greater extent and help the drug to be available.
According to the new version of the medical insurance price, the annual treatment cost of Teriplizumab will be reduced by more than 25% on the basis of the charity assistance program.
About Teriprolizumab Injection (Tuoyi®)
As the first domestically-made monoclonal antibody drug targeting PD-1 that was approved for marketing in my country, Teriprizumab Injection (Tuoyi®) has won the support of a major national science and technology project.
The first indication approved for this product is for the treatment of unresectable or metastatic melanoma that has previously failed systemic treatment, and it has been awarded the 2019 and 2020 editions of the Chinese Society of Clinical Oncology (CSCO) Melanoma Diagnosis and Treatment Guidelines recommend.
In December 2020, Tuoyi® successfully passed the national medical insurance negotiation and was included in the new version of the catalog.
In February 2021, Tuoyi® was approved by the NMPA for the treatment of patients with recurrent/metastatic nasopharyngeal carcinoma who had previously failed second-line and above systemic treatments.
In May 2020, Tuoyi®'s new indications for the treatment of patients with locally advanced or metastatic urothelial cancer who had failed or intolerated systemic treatments were accepted by the National Medical Products Administration (NMPA).
It was included in the priority review process by NMPA in July 2020.
In September 2020, Tuoyi® for the treatment of nasopharyngeal cancer was approved by the U.
Food and Drug Administration (FDA) as a breakthrough therapy.
In February 2021, the marketing application for new indications of teriprizumab combined with chemotherapy for advanced first-line recurrent and metastatic nasopharyngeal carcinoma that has not received systemic treatment was accepted by NMPA.
At present, Tuoyi® has been awarded 1 breakthrough therapy designation, 1 fast track designation and 3 orphan drug designations by the FDA in the fields of mucosal melanoma, nasopharyngeal carcinoma, and soft tissue sarcoma.